Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPB vs ICNB in VATS
NCT03682354Completed
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, open-label trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Pain score (Numerical Rating Scale) at 4 hours. Started Sep 2018; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03682354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682354.